Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Terminated 2Completed 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 3Breast 1

Conditions

Stomach Neoplasms 2Pancreatic Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 910Carboplatin 788pembrolizumab 747Paclitaxel 744Bevacizumab 716Cisplatin 709Gemcitabine 621Docetaxel 584Rituximab 558Radiotherapy 548Dexamethasone 511Nivolumab 491Doxorubicin 445Fluorouracil 392Capecitabine 382Etoposide 358Pemetrexed 339Cytarabine 335Oxaliplatin 335Lenalidomide 328Prednisone 327Erlotinib Hydrochloride 323fludarabine phosphate 316Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × titanium silicide × Clear all
NCT01285557 2024-09-19

DIGEST

Taiho Oncology, Inc.

Phase 3 Terminated
361 enrolled 18 charts
Gastrointestinal

Stomach Neoplasms

NCT03382600 2024-06-11

KEYNOTE-659

Merck Sharp & Dohme LLC

Phase 2 Completed
100 enrolled 21 charts
Gastrointestinal

Stomach Neoplasms

NCT00429858 2020-09-18

Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer

University of California, San Francisco

Phase 2 Terminated
21 enrolled 8 charts
Gastrointestinal

Pancreatic Neoplasms

NCT00438100 2015-05-29

Capecitabine vs. S-1 in Unresectable or Recurrent Breast Cancer

Japan Breast Cancer Research Network

Phase 2 Completed
142 enrolled 4 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡